Assessing immune response to RSV vaccine in patients with blood cancers
Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia
This study is testing how well the RSV vaccine works in older patients with blood cancers to see if it helps boost their immune response.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Tel-Aviv Sourasky Medical Center Government |
| Locations | 1 site (Tel Aviv) |
| Trial ID | NCT06944119 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the immune response to the RSV vaccine in patients with hematological malignancies, including myeloma, lymphoma, and leukemia. Participants aged 60 and older will undergo blood tests before and one month after vaccination to measure serological responses, neutralizing antibodies, and cellular responses. The study aims to determine the effectiveness of the vaccine in this immunocompromised population, with follow-up assessments over a 12-month period to monitor RSV incidence. The research is conducted at the Hematology Institute at Ichilov, focusing on a sample size of 250 patients.
Who should consider this trial
Good fit: Ideal candidates are patients aged 60 and older diagnosed with multiple myeloma, lymphoma, chronic lymphocytic leukemia, myelodysplastic syndrome, or acute leukemia.
Not a fit: Patients who have previously been vaccinated against RSV or have had severe reactions to vaccines may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of vaccine efficacy in immunocompromised patients, potentially leading to improved vaccination strategies.
How similar studies have performed: Previous studies have shown varying immune responses to vaccines in similar populations, but this specific approach in hematological oncology patients is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 60 years and older * Patients diagnosed with multiple myeloma(MM) or lymphoma or CLL or myelodysplastic syndrome (MDS) or acute leukemia Exclusion Criteria: * Patients who have been previously vaccinated against RSV * Patients who have experienced a severe reaction to any vaccine in the past
Where this trial is running
Tel Aviv
- Tel Aviv Sourasky Medical Center — Tel Aviv, Israel (Recruiting)
Study contacts
- Principal investigator: Irit Avivi, MD — Tel-Aviv Sourasky Medical Center
- Study coordinator: Irit Avivi, MD
- Email: iritavi@tlvmc.gov.il
- Phone: +972 3-6974452
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.